Pain Relief - Tramadol Versus Ibuprofen
|ClinicalTrials.gov Identifier: NCT00111046|
Recruitment Status : Unknown
Verified May 2005 by Royal Liverpool University Hospital.
Recruitment status was: Active, not recruiting
First Posted : May 17, 2005
Last Update Posted : November 10, 2005
|Condition or disease||Intervention/treatment||Phase|
|Choroidal Melanoma Melanoma Eye Neoplasms||Drug: Ibuprofen Drug: Tramadol||Phase 1 Phase 2|
Patients with choroidal melanomas who are offered ruthenium plaque radiotherapy have their plaque sutured to the sclera under general anaesthesia. The plaque is removed in a few days after delivering the required radioactive dosage to the tumour. While the plaque is in situ, patients require analgesia. The management of post-operative pain is generally not considered a high priority, more importance being given to the regression of the melanoma.
This is indicated by the lack of any study addressing this aspect of care. The failure of patients in general, to complain, may perhaps be due to them having accepted that some degree of pain following 'major surgery for a malignant ocular condition' is the norm.
As per current protocol, ibuprofen is being prescribed, unless contraindicated. Although many are comfortable, others request additional analgesics. Most opioid analgesics provide better pain relief but are associated with nausea, vomiting, constipation and respiratory depression.
Tramadol is an opioid analgesic that is reported to have less of the above mentioned side affects.
Comparisons: To compare the analgesic effect of oral tramadol versus ibuprofen in such patients.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Post-Operative Pain Relief Following Insertion of Radioactive Plaque for Choroidal Melanoma: Randomised Control Trial of Tramadol Vs Ibuprofen: A Pilot Study|
|Study Start Date :||February 2001|
|Study Completion Date :||February 2004|
U.S. FDA Resources
- Compare levels of pain
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00111046
|Royal Liverpool University Hospital|
|Liverpool, Merseyside, United Kingdom, L8 0RU|
|Principal Investigator:||Bertil Damato||Royal Liverpool University Hospital|